A detailed history of Quadrant Capital Group LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 1,017 shares of REGN stock, worth $708,899. This represents 0.08% of its overall portfolio holdings.

Number of Shares
1,017
Previous 1,018 0.1%
Holding current value
$708,899
Previous $1.07 Million -0.0%
% of portfolio
0.08%
Previous 0.08%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$1024.09 - $1201.76 $1,024 - $1,201
-1 Reduced 0.1%
1,017 $1.07 Million
Q2 2024

Aug 12, 2024

BUY
$883.2 - $1071.19 $45,043 - $54,630
51 Added 5.27%
1,018 $1.07 Million
Q1 2024

May 15, 2024

BUY
$902.69 - $993.35 $7,221 - $7,946
8 Added 0.83%
967 $930,000
Q4 2023

Feb 08, 2024

BUY
$775.18 - $881.7 $38,759 - $44,085
50 Added 5.5%
959 $842,000
Q3 2023

Nov 14, 2023

SELL
$692.45 - $844.37 $1,384 - $1,688
-2 Reduced 0.22%
909 $748,000
Q2 2023

Aug 09, 2023

SELL
$700.03 - $830.35 $31,501 - $37,365
-45 Reduced 4.71%
911 $654,000
Q1 2023

May 11, 2023

BUY
$680.49 - $826.97 $83,700 - $101,717
123 Added 14.77%
956 $785,000
Q4 2022

Feb 10, 2023

BUY
$705.89 - $766.39 $34,588 - $37,553
49 Added 6.25%
833 $601,000
Q3 2022

Nov 10, 2022

BUY
$573.97 - $724.32 $85,521 - $107,923
149 Added 23.46%
784 $540,000
Q2 2022

Aug 09, 2022

BUY
$548.35 - $738.84 $35,642 - $48,024
65 Added 11.4%
635 $375,000
Q1 2022

May 06, 2022

BUY
$595.12 - $698.43 $18,448 - $21,651
31 Added 5.75%
570 $398,000
Q4 2021

Feb 01, 2022

BUY
$543.48 - $670.97 $15,217 - $18,787
28 Added 5.48%
539 $340,000
Q3 2021

Nov 12, 2021

BUY
$574.03 - $680.96 $30,423 - $36,090
53 Added 11.57%
511 $309,000
Q2 2021

Aug 09, 2021

BUY
$472.8 - $558.54 $11,347 - $13,404
24 Added 5.53%
458 $256,000
Q1 2021

May 12, 2021

BUY
$446.73 - $548.2 $49,140 - $60,302
110 Added 33.95%
434 $205,000
Q4 2020

Feb 16, 2021

BUY
$478.3 - $607.98 $6,696 - $8,511
14 Added 4.52%
324 $157,000
Q3 2020

Nov 13, 2020

BUY
$544.75 - $658.21 $11,984 - $14,480
22 Added 7.64%
310 $174,000
Q2 2020

Aug 13, 2020

SELL
$493.32 - $643.92 $200,781 - $262,075
-407 Reduced 58.56%
288 $180,000
Q1 2020

May 15, 2020

BUY
$336.18 - $494.43 $143,548 - $211,121
427 Added 159.33%
695 $333,000
Q4 2019

Feb 03, 2020

BUY
$274.13 - $376.51 $64,146 - $88,103
234 Added 688.24%
268 $95,000
Q3 2019

Oct 24, 2019

SELL
$273.46 - $318.39 $129,620 - $150,916
-474 Reduced 93.31%
34 $7,000
Q2 2019

Jul 24, 2019

BUY
$299.6 - $414.82 $45,539 - $63,052
152 Added 42.7%
508 $154,000
Q1 2019

Apr 29, 2019

BUY
$372.08 - $439.57 $92,275 - $109,013
248 Added 229.63%
356 $141,000
Q4 2018

Jan 17, 2019

BUY
$335.82 - $403.04 $17,798 - $21,361
53 Added 96.36%
108 $32,000
Q3 2018

Oct 29, 2018

BUY
$351.14 - $408.51 $2,457 - $2,859
7 Added 14.58%
55 $19,000
Q2 2018

Aug 09, 2018

SELL
$284.6 - $344.99 $8,253 - $10,004
-29 Reduced 37.66%
48 $13,000
Q1 2018

May 10, 2018

SELL
$315.82 - $393.78 $6,948 - $8,663
-22 Reduced 22.22%
77 $23,000
Q4 2017

Jan 31, 2018

BUY
$358.63 - $469.95 $6,813 - $8,929
19 Added 23.75%
99 $30,000
Q3 2017

Oct 13, 2017

SELL
$431.38 - $504.0 $6,902 - $8,064
-16 Reduced 16.67%
80 $31,000
Q2 2017

Aug 15, 2017

BUY
N/A
96
96 $38,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $74.7B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Quadrant Capital Group LLC Portfolio

Follow Quadrant Capital Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.